Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes
|ClinicalTrials.gov Identifier: NCT02013557|
Recruitment Status : Terminated (Resources allocated elsewhere.)
First Posted : December 17, 2013
Last Update Posted : January 6, 2016
Purpose: The purpose of this study is to see whether a text-message reminder system will increase the number of women who complete their diabetes screening after delivery.
Study Design: Prospective randomized control trial
Hypothesis: Gestational diabetics will be significantly more likely to follow up with their postpartum screening for diabetes if they receive text-message reminders to set up their lab appointment compared to those who receive usual care.
|Condition or disease||Intervention/treatment|
|Diabetes, Gestational||Behavioral: Text-message reminder|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||57 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes|
|Study Start Date :||January 2014|
|Primary Completion Date :||December 2015|
|Study Completion Date :||December 2015|
Experimental: Intervention Group
Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
|Behavioral: Text-message reminder|
No Intervention: Control group
This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
- Percentage of patients that receive the 2-hour 75-g oral glucose tolerance test [ Time Frame: Within six months of their delivery date ]
- Percentage of patients that receive any type of postpartum diabetes screening [ Time Frame: Within six months of their delivery date ]This can include any of the multiple forms of diabetes screening tests including: 75-g oral glucose tolerance test, Hemoglobin A1c, fasting plasma glucose test or others.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02013557
|United States, Florida|
|Tampa General Hospital|
|Tampa, Florida, United States, 33606|
|Principal Investigator:||Judette Louis, MD||University of South Florida Department of Obstetrics and Gynecology|
|Study Chair:||Angela Gonzalez, MD||University of South Florida Department of Obstetrics and Gynecology|